Search
Matt Callahan said the product received an excellent safety profile.

Botanix up on study results

Shares in medical dermatology company Botanix Pharmaceuticals, led by Perth-based chairman Graham Griffiths and executive director Matt Callahan, jumped more than 20 per cent today after the company announced successful results from an acne patient study.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/06/18

1 year TSR5 year TSR
69thBotanix Pharmaceuticals164%106%
722 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

27/04/18
$19k Bought
27/04/18
$94k Sold
27/04/18
$25k Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

211th↓Botanix Pharmaceuticals$0
239 listed industrial companies ranked by revenue.
Source: Morningstar

Remuneration from Botanix Pharmaceuticals

385thRobert Towner$60k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer